| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a University of California Los Angeles, Los Angeles, California, USA; b Hôpital Saint Louis, University of Paris, Paris, France; c Centre University and Luxembourg Medical Centre, Luxembourg; d Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA; e PROCRIT Study Group
Correspondence: George D. Demetri, M.D., Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-623-3985; Fax: 617-623-3408; e-mail:george_demetri{at}dfci.harvard.edu
Background. Data from two large, community-based clinical trials that evaluated the efficacy of epoetin alfa in anemic cancer patients receiving chemotherapy were retrospectively analyzed to determine if clinical outcomes were different depending on whether chemotherapy was platinum- or nonplatinum-based.
Patients and Methods. Patients received epoetin alfa 150-300 IU/kg (Glaspy: Study 1; n = 2,342) or 10,000-20,000 IU (Demetri: Study 2; n = 2,370) s.c. three times each week for 4 months. Efficacy end points were changes in transfusion requirements, hemoglobin (Hb) levels, and quality of life (QOL). A total of 4,298 out of 4,712 patients (platinum-based, n = 1,601; nonplatinum-based, n = 2,697), who both received chemotherapy and had available data, were eligible for this retrospective analysis.
Results. Baseline characteristics across groups were comparable with few exceptions, which were anticipated in view of the characteristics of the two different chemotherapy types. Decreases in transfusion requirements after 2, 3, and 4 months were significant, regardless of chemotherapy type. Mean increases in Hb level from baseline to final evaluation ranged from 1.6 g/dl to 2.0 g/dl across study groups and were significant, regardless of chemotherapy type. QOL, as measured by the Linear Analog Scale Assessment (LASA), improved significantly by 20%-43%, regardless of chemotherapy type, and improvements were associated with increases in Hb. Epoetin alfa was well tolerated in both studies, regardless of chemotherapy type.
Conclusion. Treatment of anemic cancer patients with epoetin alfa results in significant reduction in transfusion requirements, increase in Hb levels, and improvements in QOL, regardless of whether the chemotherapy is platinum- or nonplatinum-based.
This article has been cited by other articles:
 |
|
 |
|
  J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow Mechanisms of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 22 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watson and V. Mock Exercise as an Intervention for Cancer-Related Fatigue Physical Therapy, August 1, 2004; 84(8): 736 - 743. [Full Text] [PDF]
|
|
|
|
|
|
E. Cortesi, A. Mancuso, A. De Pasquale Ceratti, N. Pizzardi, G. D'Auria, C. Accettura, P. Beccaglia, D. Bertelletti, and F. De Marinis Effectiveness and Safety of an Induction Therapy with Epoetin Alfa in Anemic Cancer Patients Receiving Concomitant Chemotherapy Oncologist, July 1, 2004; 9(4): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dicato Anemia in Cancer: Some Pathophysiological Aspects Oncologist, February 1, 2003; 8(90001): 19 - 21. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
